TECNOTREE
4.8.2022 11:23:07 CEST | Business Wire | Press release
On Thursday, August 4, 2022, Tecnotree announced its financial results for the second quarter ended June 30, 2022. Tecnotree, the global Digital Business Support Systems (BSS) provider, reported a revenue of EUR 18.3 million in the second quarter, continuing its financial strength with considerable growth in MEA & APAC segments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220804005494/en/
Consolidated highlights of the results of Q2 and Half Year 2022:
- Net sales of EUR 18.3 million in the second quarter, showing 9% growth as compared to last year, and EUR 31.6 million for H1 with 13% growth from last year
- Operating result of EUR 5.1 million in the second quarter, and EUR 7.1 million for H1
- Earnings per share of EUR 0.01 in the second quarter, and EUR 0.02 for H1
- Order book at the end of the period EUR 72.8 million, with 32.4% growth as compared to last year
Tecnotree CEO Padma Ravichander said, “Our customers have responded to our digital stack offering, with a strong order book for which we need to invest to deliver expeditiously. Despite rising costs due to external factors leading to thinner first-half net result margins, we continue to deliver new deployments to Tier-1 clients, which requires a greater initial investment. This investment today will ensure long-term recurring revenue over the next 3-5 years with our new customers by bringing stability. Our Digital Stack 5.0 is richer and capable of serving multiple markets and customers simultaneously.”
Other achievements for the second quarter:
- Achieving the highest order book position of EUR 72.8 million - 32% higher than H1 in 2021, due to a surge in demand for Tecnotree products and solutions in the first half of 2022, with continued support from large tier 1 telecom groups such as MTN, STC, Zain, Ooredoo
- Tecnotree digital BSS suite 5 went live for enterprise and consumer businesses for MTN Uganda, driving process agility and customer delight
- Launch of digital transformation suite for MTN Ghana to meet enterprise market demand and deliver augmented customer experiences
- Tecnotree Awarded as 'Change-maker of the year' by the Helsinki Stock Exchange Foundation, for being instrumental in driving growth in emerging markets with its 5G-ready digital products and solutions
- Launch of 5G cloud-native Digital Provisioning Platform for Zain South Sudan, and another tier 1 operator in the Middle East. Tecnotree DSPS is a pre-integrated suite that enables a centralized system for all provisioning-related planning and task management
- Tecnotree wins ‘MongoDB Independent Software Vendor (ISV) Partner of the Year - Telco’ for enabling customers to transition to new technologies and digital ecosystems
- Launch of DOCS, a 5G Digital Convergent Charging Platform which supports existing and futuristic monetization requirements of CSPs across the verticals and industries
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) provider, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is among the first companies in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com or social media channels – LinkedIn I Facebook I Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005494/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom